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Abstract
Introduction Our objective was to determine whether markers
of bone resorption and formation could serve as markers for the
presence of bone marrow lesions (BMLs).
Methods We conducted an analysis of data from the Boston
Osteoarthritis of the Knee Study (BOKS). Knee magnetic
resonance images were scored for BMLs using a
semiquantitative grading scheme. In addition, a subset of
persons with BMLs underwent quantitative volume
measurement of their BML, using a proprietary software method.
Within the BOKS population, 80 people with BMLs and 80
without BMLs were selected for the purposes of this case-
control study. Bone biomarkers assayed included type I collagen
N-telopeptide (NTx) corrected for urinary creatinine, bone-
specific alkaline phosphatase, and osteocalcin. The same
methods were used and applied to a nested case-control
sample from the Framingham study, in which BMD assessments
allowed evaluation of this as a covariate. Logistic regression
models were fit using BML as the outcome and biomarkers, age,
sex, and body mass index as predictors. An receiver operating
characteristic curve was generated for each model and the area
under the curve assessed.
Results A total of 151 subjects from BOKS with knee OA were
assessed. The mean (standard deviation) age was 67 (9) years
and 60% were male. Sixty-nine per cent had maximum BML
score above 0, and 48% had maximum BML score above 1. The
only model that reached statistical significance used maximum
score of BML above 0 as the outcome. Ln-NTx (Ln is the natural
log) exhibited a significant association with BMLs, with the odds
of a BML being present increasing by 1.4-fold (95% confidence
interval = 1.0-fold to 2.0-fold) per 1 standard deviation increase
in the LnNTx, and with a small partial R2 of 3.05. We also
evaluated 144 participants in the Framingham Osteoarthritis
Study, whose mean age was 68 years and body mass index was
29 kg/m2, and of whom 40% were male. Of these participants
55% had a maximum BML score above 0. The relationship
between NTx and maximum score of BML above 0 revealed a
significant association, with an odds ratio fo 1.7 (95%
confidence interval = 1.1 to 2.7) after adjusting for age, sex, and
body mass index.
Conclusions Serum NTx was weakly associated with the
presence of BMLs in both study samples. This relationship was
not strong and we would not advocate the use of NTx as a
marker of the presence of BMLs.
Introduction
Research into the etiology and progression of knee osteoar-
thritis (OA) has focused on the destruction of articular carti-
lage. However, it is clear that knee OA is an organ-level failure
of the joint and involves pathologic changes in articular carti-
lage as well as in subchondral bone [1].
BMD: bone mineral density; BMI: body mass index; BML: bone marrow lesion; BOKS: Boston Osteoarthritis Knee Study; BSAP: bone-specific alka-
line phosphatase; Cr: creatinine; MRI: magnetic resonance imaging; NTx: type I collagen N-telopeptide; OA: osteoarthritis.
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The structural properties of subchondral bone may play a role
in the degeneration of cartilage [2], and adjoining trabecular
changes are considered necessary for the progression of OA
[3]. In OA, bone has characteristic morphologic abnormalities,
including altered joint congruency, bone marrow lesions
(BMLs) [4], subchondral sclerosis, intraosseous cysts, and
osteophytes.
BMLs are high-signal lesions in the medullary space that
extende to subcortical bone, according to T2-weighted mag-
netic resonance imaging (MRI) [5]. The earliest investigations
reflecting this disturbance were conducted using scintigraphy
[6-8]. This work suggested that not only was the activity of the
subchondral bone altered, but also this may determine the rate
of loss of cartilage. In work from the Boston Osteoarthritis
Knee Study (BOKS), BMLs on MRI were found to be strongly
associated with the presence of pain in knee OA [4].
More importantly from the perspective of prognostic markers,
the BOKS study findings suggested that BMLs are a powerful
independent predictor of OA progression (joint space loss
over time on fluoroscopically positioned x-ray) in persons with
painful knee OA, and their presence identified most knees at
risk for progression [9]. These findings replicate an earlier nat-
ural history study [7] in which bone scan lesions were found to
powerfully predict radiographic progression in the knees.
On bone histology, areas of bone affected by BMLs exhibit
reversal lines indicative of bone remodeling [10]. Small areas
of bone necrosis are also present, as is scar. The extensive
bone remodeling seen, and the correlation of MRI bone mar-
row lesions with positive bone scintigraphy (a tracer that is
picked up by osteoblasts) both strongly suggest that bone
turnover is markedly increased in these local areas.
Other evidence supporting a high rate of turnover in advancing
OA emanates from studies suggesting that there is increased
synthesis and degradation of the subchondral bone collagen
in OA, as well as changes to post-translational modifications
[11,12]: increased lysine hydroxylation, changes in the nature
of the cross-links between the polypeptide chains, and conse-
quent decreased mineralization.
Subjacent to the thickened cortical plate, studies have
reported hypomineralization of trabecular bone [13-15]. This
localized loss of bone mass is possibly linked to abnormal
bone cell behavior in OA joints, reported as imbalances in
bone resorption, formation, or both [16]. Recent studies have
confirmed that increased bone resorption plays an integral role
in the disease process, with increased levels of bone resorp-
tion markers reported in patients with radiographic evidence of
knee OA, including type I collagen [17] and deoxypryidinoline
[18]. In addition to bone being lost locally within the diseased
joint, altered bone has been reported in OA patients at sites
distant from weight-bearing joints [19], and low hip BMD
appears to be correlated with OA knee progression [20,21].
One explanation for this change is that there is rapid turnover
of subchondral bone in OA, and there is insufficient time for
the bone to be adequately mineralized. It is not known whether
these areas of abnormal bone are derived from areas that
would generate BML findings on MRI.
We hypothesized that if bone marrow lesions are areas of
accelerated bone turnover, then they should be accompanied
by elevation in systemic levels of bone turnover markers. If our
hypothesis is correct, namely that bone turnover markers are
associated with BMLs and that – like BMLs – they predict car-
tilage loss, then this will provide important insights into the
pathophysiology of OA and may provide a biomarker that, like
the BML that it reflects, may potently predict cartilage loss.
Materials and methods
We conducted a cross-sectional analysis of data from two
sources: BOKS and the Framingham Osteoarthritis Study.
Within each study 80 people with BMLs and 80 without BMLs
were chosen for a nested case-control sample.
BOKS Sample
We conducted a cross-sectional analysis of data from the
Boston Osteoarthritis of the Knee Study (BOKS) [22] – a
completed natural history study of knee OA. To be eligible for
inclusion in the study, a person had to have knee pain, aching
or stiffness on most days within the preceding month, and they
had to have reported that a physician had told them that they
had arthritis in the knee. If they met both of those criteria then
they underwent radiography (weight-bearing fluoroscopic
posteroanterior (PA), lateral, and skyline views), and if on any
of these views they had a definite osteophyte in the sympto-
matic knee, then they were eligible for inclusion in the study. In
addition, if they screened positive for another form of arthritis
or were using medications that were appropriate for rheuma-
toid or other forms of arthritis, then they were excluded. Thus,
all of those included in the study had primary clinical knee OA
and met American College of Rheumatology criteria for this
disorder [23].
Of 324 patients who entered the study, 86% completed a full
comprehensive follow up at a later time point (either 15 or 30
months, or both). Comprehensive examinations consisted of
an MRI of the more affected knee and a comprehensive set of
radiographs, including a semiflexed fluoroscopically posi-
tioned PA radiograph using the method of Buckland-Wright
[24].
Fasting blood and urine specimens were also obtained at
baseline. Serum was frozen at -70°C and urine at -20°C. The
specimens were stored at the Biomedical Research Institute in
Rockville (MD, USA).
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For grant funding reasons, we were funded to perform biomar-
kers on 160 of these participants. We conducted a nested
study of persons within BOKS who had and did not have
BMLs. After completion of the assays, data were available for
all of the biomarker assays for 153 participants. Upon merging
the biomarker assay data and MRI data, complete data (both
complete biomarker and MRI data) were available for analysis
in 151 participants. These participants were similar in age and
sex distribution to those from the larger study sample.
The institutional review boards of Boston University Medical
Center and the Veterans Administration Boston Health Care
System approved the baseline and follow-up examinations.
Informed consent was obtained from all study participants.
Framingham sample
The Framingham study cohort consisted of two separate
groups as follows: members of the Framingham Heart Study
Offspring cohort, and a newly recruited cohort from the town
of Framingham (MA, USA). Participants in this combined
group, designated the 'Framingham Osteoarthritis Study
cohort', were examined in 2002 to 2005.
Participants in the Framingham Heart Study Offspring cohort
included surviving descendants (and spouses of descend-
ants) of the original Framingham Heart Study cohort [25]. As
part of a study of the inheritance of OA, selected participants
in the Offspring cohort were originally examined between
1992 and 1994. Members of this group were identified as
potential participants in the present study. All were contacted
by telephone and invited to participate in the study. A validated
survey instrument [26] supplemented by questions about
medication use reflecting treated rheumatoid arthritis was
used to exclude patients with rheumatoid arthritis.
The newly recruited cohort participants were drawn from a
random sample from the Framingham, Massachusetts commu-
nity. Flyers were hung in public areas to increase awareness of
the study, which was focused on health, including bone health,
foot health, and arthritis. Participants were recruited using ran-
dom-digit dialing and census tract data to ensure that a repre-
sentative sample of the Framingham community was recruited.
To be included, individuals had to be at least 50 years old and
ambulatory (use of assistive devices such as canes and walk-
ers was allowed). Exclusion criteria were the presence of bilat-
eral total knee replacements and the presence of rheumatoid
arthritis. In neither Framingham group was participant selec-
tion based on the presence or absence of knee OA. The insti-
tutional review board of Boston University Medical Center
approved the examinations.
Fasting blood and urine specimens were also obtained at the
visit. For all participants biologic specimens were available,
within 2 days, serum was frozen at -70°C and urine was frozen
at -20°C. They were both then stored centrally at -70°C at the
Biomedical Research Institute in Rockville (MD, USA).
After completion of the assays, data were available for all of the
biomarker assays in 150 participants. Upon merging the
biomarker assay data and MRI data, complete data (both com-
plete biomarker and MRI data) were available for analysis in
144. These participants were similar to those from the larger
study sample.
Measures taken in both studies
Age, sex, and body mass index (BMI) were assessed in all
study participants. BMI was calculated, using Quetelet's
index, as weight (in kilograms) divided by height (in meters)
squared. Height was measured using a stadiometer, and
weight was measured using a balance beam scale.
Magnetic resonance imaging
All subjects underwent a sagittal and a coronal T2 turbo-spin
echo with fat suppression. The magnetic resonance system
and pulse sequences for BOKS [22] and Framingham [27]
have previously been described. Two different measures were
used to define BMLs; a semiquantitative score and a quantita-
tive BML volume.
BMLs were defined as ill-defined areas adjacent to the subar-
ticular bone of hypointense signal on T1-weighted images and
hyperintense signal on T2-weighted fat-suppressed images.
Using the whole-organ MRI score system (WORMS) for sag-
ittal images, each lesion was graded on a scale from 0 to 3,
based on the extent of regional involvement [28]. BMLs were
graded in each of 14 articular surface regions. The readers
who performed all of the readings were blinded to the patients'
characteristics and biomarker readings. Interobserver agree-
ment for WORMS BML scores was good (intraclass correla-
tion coefficients 0.69 to 0.88).
In addition, a subset of persons with BMLs underwent quanti-
tative volume measurement of their BMLs using a proprietary
software method (VirtualScopics, Rochester, NY, USA). BML
volume (ml) was characterized using a BML segmentation
multi-spectral match filter method. For the analyses presented
here the BML volume refers to the total BML volume for the
whole knee.
Bone density measurement
In addition, the Framingham participants underwent measure-
ment taken of bone mineral density (BMD). Because bone
density may influence the levels of bone biomarkers and
BMLs, we chose to use this as a covariate in our analyses. In
our study, the data available for assessment of BMD were val-
ues for the femoral neck and lumbar spine. Because the inter-
pretation of spine BMD can be complicated by the presence
of compression fractures and degenerative disease, we chose
femoral neck BMD as the better measure of systemic BMD.
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Measurements (in g/cm2) were obtained using dual-energy X-
ray absorptiometry (Lunar Prodigy scanner; GE Lunar, Madi-
son, WI, USA). The right femur was scanned unless there was
a history of a previous fracture or joint replacement, in which
case the left femur was scanned. We used standard position-
ing, as recommended by the manufacturer. For quality assur-
ance, we scanned phantoms provided by the manufacturer
under varying thicknesses of oil and water. No drift in BMD
measurements was observed over time. We analyzed the prox-
imal femur using the manufacturer's standard protocol, focus-
ing on the femoral neck region for these analyses.
Bone biomarkers
Biochemical markers of bone turnover were assayed in
archived serum and urine stored at -70°C. We measured two
serum bone formation markers: osteocalcin and bone-specific
alkaline phosphatase (BSAP).
BSAP was measured using a monoclonal antibody that exhib-
its specificity for BSAP (Alkphase-B; Metra Biosystems,
Mountain View, CA, USA), thus providing a quantitative meas-
ure of BSAP activity in serum as a measure of osteoblastic
activity. The sensitivity is 0.7 U/l, and the intra-assay and inter-
assay coefficients of variation at 28 U/l were 3.3% and 7.9%,
respectively [29].
For osteocalcin, we used the US Food and Drug Administra-
tion approved Nordic Bioscience N-MID assay instead of an
assay for intact osteocalcin. The reason for this is that circulat-
ing osteocalcin is unstable because it contains a tryptic cleav-
age site at amino acids 43 to 45 near to the carboxyl-terminus
[30]. After cleavage, a large fragment containing amino acids
1 to 43 is formed, which is termed N-MID because it contains
the amino (N)-terminus and middle portion of the protein.
Whereas the levels of intact osteocalcin rapidly decreases, the
total pool of intact osteocalcin and N-MID fragments remains
stable in serum, even after repeated freeze thaw cycles or stor-
age at elevated temperatures [31]. The N-MID osteocalcin
enzyme-linked immunosorbent assay developed by Nordic
Bioscience Diagnostics (Herlev, Denmark) measures the total
pool of intact osteocalcin and N-MID fragments with equal
affinity, ensuring reliable and robust measurements [31].
A bone resorption marker, type I collagen N-telopeptide (NTx)
was measured in urine and corrected for urinary creatinine.
Measurements of urinary NTx (nmol bone collagen equiva-
lents/mmol creatinine) were performed by enzyme-linked
immunosorbent assay (Osteomark NTx Urine; Ostex Interna-
tional, Seattle, WA, USA). The intra-assay coefficient of varia-
tion for this assy ranges from 5% to 19%. Urinary NTx values
were normalized versus urinary creatinine to account for uri-
nary dilution [32].
All assay measures were conducted at TNO (Leiden, The
Netherlands). The assays were conducted blinded to out-
comes.
Analysis
Because of the effects of estrogen and bisphosphonates on
bone remodeling markers, patients receiving these medica-
tions were removed from the analysis. Because of marked
skewness, the natural log of each biomarker was used to pre-
dict BML. To facilitate comparison between the biomarkers,
we used the standardized distribution of each biomarker as
the predictor. We classified each participant according to
maximum score of any BML (ordinal scale 0 to 3) and two
binary outcomes: maximum score of BML > 0 and maximum
score of BML > 1. We used contingency tables to assess lev-
els of each biomarker in relation to status of BMLs. Logistic
regression models were fit using BML as the outcome and
biomarkers, age, sex, and BMI as predictors. A receiver oper-
ating characteristic curve was generated for each model, and
the area under the curve was assessed. Finally, the biomarkers
were used as predictors of quantitative BML volume in a linear
regression.
The benefit of doing this analysis in Framingham was that it
allowed us to adjust for the potential confounding influence of
BMD. In addition, Framingham study had data on two knees;
for this analysis a generalized estimating equation correction
was used.
We also conducted exploratory analyses to assess whether
bone biomarkers were associated with cartilage loss on MRI
in the BOKS sample. We assessed whether increased levels
of each biomarker was predictive of subsequent cartilage loss
on knee MRI (ascertained from baseline to 30 month visit). We
performed a logistic regression to examine the relation of level
of NTx to the risk for cartilage loss in any plate. Cartilage loss
was defined as an increase in cartilage score in any of the
plates previously mentioned.
Results
BOKS analyses
A total of 151 individuals with knee OA were assessed (Table
1). The mean (standard deviation) age was 67 (9) years and
60% were male. Sixty-nine per cent of participants had a max-
imum BML score > 0 and 48% had a maximum BML score >
1.
On investigation of the relation between biomarkers and sem-
iquantitative BMLs, the only model that achieved statistical sig-
nificance used maximum score of BML > 0 as the outcome.
Results of this model are shown in Table 2. Although the over-
all model (including age, sex, and BMI) predicting BMLs was
statistically significant for each biomarker, neither Ln-BSAP or
Ln-osteocalcin exhibited a statistically significant univariate
association with BMLs, regardless of how BMLs were defined.
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Ln-NTx exhibited a significant association with BMLs, with the
odds of a BML being present increasing by 1.4-fold (95% con-
fidence interval = 1.0-fold to 2.0-fold) per 1 standard deviation
increase in the LnNTx, and with a small partial R2 of 3.05. For
Ln-BSAP, there was a modest nonsignificant association, with
the odds of a BML being present increasing 1.4-fold per 1
standard deviation increase in the Ln-BSAP.
A model that contained all three biomarkers together with age,
sex, and BMI was also fit. This model had an R2 value of
18.84%, which was significantly greater than the values for
models with only one marker (likelihood ratio F2 = 21.1 on six
degrees of freedom; P = 0.002). The odds ratios for this
model were similar to those in the univariate models (odds
ratio [95% confidence interval]): Ln-BSAP, 1.3 (0.9 to 2.0);
Ln-osteocalcin, 1.2 (0.8 to 1.7); and Ln-NTx, 1.3 (0.9 to 2.0).
No significant relationship was found between biomarkers and
quantitative BML volume in linear regression models in the 47
BOKS participants in whom BML volume was quantified. The
exploratory analysis of standardized biomarkers of cartilage
loss on MRI did not reveal any significant associations. The
odds ratio (95% confidence interval) for Ln-NTx predicting
cartilage loss after adjusting for age, sex, and BMI was 1.06
(0.76 to 1.48).
Framingham analyses
A total of 144 participant in the Framingham Osteoarthritis
Study were studied (Table 3). Their mean age was 68 years,
their BMI was 29 kg/m2, and 40% of them were male. Fifty-five
per cent of participants had a maximum BML score > 0.
On investigation of the relation between biomarkers and sem-
iquantitative BML, we did not find a significant relationship
between BSAP and osteocalcin and BML > 0 (Table 4). The
relationship between NTx and maximum score of BML > 0
revealed a significant association, with an odds ratio of 1.7
(95% confidence interval 1.1 to 2.6) after adjusting for age,
sex, and BMI. After further adjusting for the presence of OA
(Kellgren and Lawrence t 2), the parameter estimates
remained the same but the confidence limits were wider and
the results no longer significant. On adding 'gender' as a pre-
dictor into the model there was no significant interaction, and
so the sexes were combined. In the Framingham analysis, we
had data for two knees, so generalized estimating equation
was used; hence, there is no R2 for this model.
On assessment of the relation between biomarkers and quan-
titative BML volume, no significant relationship was found
between BSAP and quantitative BML volume in linear regres-
sion models (Table 5). In contrast, both osteocalcin and NTx
exhibited a positive association (P < 0.04) after adjusting for
femoral neck BMD.
Discussion
Serum NTx appears to be consistently weakly associated with
the presence of BMLs. Based on the these results the effect
of NTx is small and not clinically meaningful. Other individual
bone biomarkers (osteocalcin and BSAP) do not appear to be
consistently associated with the presence of BMLs.
Bone is a specialized connective tissue with an extensive
extracellular matrix that has the unique ability to become calci-
fied, thereby forming, in conjunction with cartilage, key compo-
nents of the skeletal system. Its metabolism is characterized by
two opposing processes: formation and resorption. Typically,
diseases of bone are characterized by an alteration in the bone
resorption/formation balance, and our initial hypothesis was
Table 1
Characteristics of the BOKS study population
Parameter Value
Age (years; mean ± SD [range]) 67 ± 9 (50 to 93)
Sex (n [%] male) 91 (60%)
Proportion with BML > 0 69.5%
NTx/Cr (nM/mM; mean ± SD) 0.06 ± 0.12
BSAP (U/l; mean ± SD) 37.5 ± 23.2
Osteocalcin (U/l; mean ± SD) 19.2 ± 15.6
There were 151 participants. BOKS, Boston Osteoarthritis Knee 
Study; BSAP, bone-specific alkaline phosphatase; NTx/Cr, type I 
collagen N-telopeptide corrected for urinary creatinine; SD, standard 
deviation.
Table 2
BOKS analysis: independent association of standardized biomarkers with BML (BML > 0) per SD of change in marker
Univariate association Full model (including age, sex and BMI)
Marker (BML = 0) (BML > 0) OR 95% CI R2 Full model R2 Full model ROC area
Ln-BSAP 3.48 (0.35) 3.57 (0.36) 1.4 (0. 9, 2.0) 2.58 14.56 0.701
Ln-osteocalcin 2.73 (0.51) 2.80 (0.55) 1.2 (0.8, 1.7) 0.8 13.41 0.687
Ln-NTx -3.47 (1.07) -3.27 (0.78) 1.4 (1.0, 2.0) 3.05 14.55 0.697
BMI, body mass index; BML, bone marrow; BOKS, Boston Osteoarthritis Knee Study; BSAP, bone-specific alkaline phosphatase; Ln, Natural 
Log; NTx, type I collagen N-telopeptide; SD, standard deviation.
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that the presence of BMLs would be associated with a distur-
bance in bone turnover. This disturbance in turnover appears
to be more consistent with increased resorption than forma-
tion, based upon our findings in the present study. This
remains consistent with the notion that persons with knee OA
are likely to have higher bone turnover than persons without
OA based on other studies, and that BMLs may reflect a proxy
for radiographic OA [18,33,34]. When we further investigated
the sample of persons in Framingham to explore this further,
there was almost complete concordance with persons who
had a BML > 0 and persons with radiographic knee OA (K&L
t 2).
A number of cross-sectional studies have been conducted in
OA that suggest that bone biochemical markers may be help-
ful in predicting progressive disease, although results are
inconsistent. Garnero and coworkers [35] conducted a cross-
sectional study of a group of 67 patients with knee OA (mean
age 64 years, median disease duration 8 years) and 67 healthy
control individuals. All bone turnover markers were decreased
in patients with knee OA as compared with control individuals
(-36%, -38%, and -52% [P < 0.0001] for serum osteocalcin,
serum CTX-I, and urinary CTX-I, respectively).
It is important to note that these findings are not consistent
with previous research, such as that showing the urinary excre-
tion of pyridinium cross-links is significantly increased in
patients with large joint OA and hand OA, suggesting an
increased rate of bone turnover [34].
Recently, Garnero and colleagues [36] examined the relation
between bone marrow abnormalities and CTX-II – a type II col-
lagen biomarker that has been shown to predict radiographic
progression in patients with knee OA [37]. Baseline CTX-II lev-
els (but not serum CTX-I levels) were correlated (r = 0.29) with
BMLs, and there was a suggestion that they predicted an
increase in BML at 3 months.
Further longitudinal data also suggests that bone turnover is
increased in OA. These data come from the population-based
Chingford study, conducted in 216 women in whom urine from
three time points was assayed for urinary collagen cross-link
excretion (urine C-telopeptide of type I collagen (CTx) and
NTx). Levels were found to be significantly elevated in knee
OA patients as compared with age-matched control individu-
als without OA, and to the same increased levels as in women
with osteoporosis. In addition, the group with progressive dis-
ease had higher levels than nonprogressors [33]. This study
was done with conventional anteroposterior radiographs of
the knee and evaluated overall changes in OA grade, and
therefore the findings may not reflect cartilage loss. Thus, the
highest quality studies suggest that bone turnover is elevated
among those with OA, possibly a result of subchondral BMLs.
The results of previous studies of osteocalcin appear to be
somewhat conflicting. A longitudinal study [38] showed that
the 1-year increase in osteocalcin was associated with loss of
joint space width in patients with knee OA over 3 years; how-
ever, the baseline measure did not predict progression of joint
space narrowing. The longitudinal Michigan Bone Health
Study [39] showed that serum osteocalcin was lower in 3-year
incident cases of hand or knee OA as compared with women
without OA.
Of the markers we studied, NTx appears to exhibit the greatest
discrimination between participants with and those without
BMLs. Type I collagen is predominant in the extracellular matrix
of bone. Cross-linked N-telopeptides (NTx) have therefore
been targeted as markers of bone resorption in urine. Elevated
Table 3
Characteristics of the Framingham study population
Age (years; mean ± SD [range]) 68.5, 9.33 (49,90)
Body mass index (kg/m2; mean ± SD) 28.87 ± 5.24
Sex (% male) 39.9%
Proportion with BML > 0 54.9%
NTx/Cr (nM/mM; mean ± SD) 0.04 ± 0.02
BSAP (U/l; mean ± SD) 16.2 ± 7.5
Osteocalcin (U/l; mean ± SD) 33.9 ± 9.9
There were 144 participants. BSAP, bone-specific alkaline 
phosphatase; NTx/Cr, type I collagen N-telopeptide corrected for 
urinary creatinine; SD, standard deviation.
Table 4
Framingham analysis: independent association of standardized biomarkers with BML (BML > 0) per SD of change in marker
Marker Adjusted for age, sex, and BMI Multi-adjusted (adjusted for age, sex, BMI, 
and BMD)
Multi-adjusted (Adjusted for OA, age, sex, BMI, 
and BMD)
Ln-BSAP 1.4 (0.9 to 2.1) 1.4 (0.9 to 2.0) 1.26 (0.75 to 2.11)
Ln-osteocalcin 1.1 (0.7 to 1.7) 1.1 (0.7 to 1.7) 1.60 (0.99 to 2.57)
Ln-NTx 1.7 (1.1 to 2.7) 1.7 (1.1 to 2.6) 1.65 (0.96 to 2.83)
Values are presented as odds ratio (95% confidence interval). BML, bone marrow; BSAP, bone-specific alkaline phosphatase; Ln, Natural Log; 
NTx, type I collagen N-telopeptide; SD, standard deviation.
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levels of urinary NTx indicate elevated human bone resorption
[40], and our data suggest that their levels are increased in
persons with BMLs. Based upon our findings, this investiga-
tive tool may assist in discriminating between persons with
and without BMLs, but this discriminatory ability is weak at
best.
There are some limitations of this work that warrant mention,
some of which are generic to the application of biomarkers.
Age-related increases are commonly seen in biochemical
markers, and these may produce variation in both biomarker
levels and BMLs [41]. Efforts were made to adjust for age in
the analyses. The BOKS and Framingham studies assessed
the local structural changes in participants' knees only. It may
be that other studies that investigate the total body burden of
OA, including other joint areas, may be able to detect an asso-
ciation in persons with symptomatic OA. Another potential
explanation for our null findings in persons with symptomatic
OA is that we have insufficient power. Similarly, bone biomar-
ker assays may reflect alterations in bone metabolism that are
present at the time the sample was collected, whereas the
BML lesion seen on an MRI reflects a structural change that
took place at some time in the past and may be stable, may
progress, or may even regress. The markers chosen are not
specific to OA but rather are likely to be altered in someone
with rapidly remodelling bone, including fractures, bone form-
ing tumours, and growing children. Furthermore, they reflect
systemic sources, and the progression or lack thereof of OA
[42], which is quite localized, may not contribute substantively
to altered levels.
Conclusion
Serum NTx was weakly associated with BMLs presence in
both study samples. Changes in other markers were not asso-
ciated consistently with the presence of BMLs. If local bone
turnover in persons with symptomatic knee OA is associated
with visible lesions, then they do not appear to affect systemic
biomarker levels markedly. Based on these data, we would not
advocate their use as markers for the presence of BMLs in per-
sons with symptomatic knee OA.
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